Are Analysts Bearish Nevro Corp (NYSE:NVRO) After Last Week?

Out of 7 analysts covering Nevro Corp (NYSE:NVRO), 6 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Nevro Corp was the topic in 7 analyst reports since August 13, 2015 according to StockzIntelligence Inc. Below is a list of Nevro Corp (NYSE:NVRO) latest ratings and price target changes.

29/03/2016 Broker: Northland Capital Rating: Market Perform New Target: $48.00 Initiate
19/01/2016 Broker: BMO Capital Markets Rating: Outperform Old Target: $75.00 New Target: $76.00 Target Up
12/01/2016 Broker: Sterne Agee CRT Rating: Buy Old Target: $80.00 New Target: $85.00 Target Up
04/01/2016 Broker: Sterne Agee CRT Rating: Buy Old Target: $68.00 New Target: $80.00 Target Up
08/12/2015 Broker: Leerink Swann Rating: Outperform Old Target: $68.00 New Target: $75.00 Target Up

About 446,042 shares traded hands. Nevro Corp (NYSE:NVRO) has risen 35.35% since September 3, 2015 and is uptrending. It has outperformed by 30.69% the S&P500.

Nevro Corp. is a medical device company. The company has a market cap of $1.71 billion. The Firm makes and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. It currently has negative earnings. The Firm developed and commercialized a neuromodulation platform for the treatment of chronic pain.

Nevro Corp - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Add Comment